Intech Investment Management Trims BridgeBio Pharma Stake

Institutional investor sells nearly 20,000 shares of biotech company

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Intech Investment Management LLC reduced its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 22.6% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor now owns 68,054 shares of the company's stock, down from 87,880 shares previously.

Why it matters

BridgeBio Pharma is a clinical-stage biotech company focused on developing treatments for genetic diseases and cancers. Institutional investor activity in the stock can provide insights into market sentiment and the company's performance.

The details

According to the 13F filing, Intech Investment Management sold 19,826 shares of BridgeBio Pharma during the third quarter. The firm's total position in the stock is now valued at $3,535,000. Other major institutional investors in BridgeBio Pharma include Vanguard Group, Geode Capital Management, and Invesco Ltd.

  • Intech Investment Management reduced its BridgeBio Pharma stake during the 3rd quarter of 2025.

The players

Intech Investment Management LLC

An institutional investor that has reduced its position in BridgeBio Pharma.

BridgeBio Pharma, Inc.

A clinical-stage biopharmaceutical company headquartered in Palo Alto, California that is developing treatments for genetic diseases and cancers.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Intech Investment Management's BridgeBio Pharma stake suggests potential investor concerns about the company's performance or outlook, though the overall institutional ownership remains high. BridgeBio's ability to advance its pipeline of genetic disease and cancer treatments will be closely watched by the investment community.